spironolactone + thiazolidinedione

**Spironolactone + thiazolidinedione** is a combination therapy consisting of two distinct pharmaceuticals—spironolactone, a potassium-sparing diuretic and aldosterone antagonist, and a thiazolidinedione, a class of insulin sensitisers most commonly represented in clinical use by pioglitazone and rosiglitazone. Spironolactone acts primarily by antagonizing the mineralocorticoid receptor, facilitating natriuresis and reducing potassium loss, thereby serving as an antihypertensive and anti-edematous agent[2][3][4][7]. Thiazolidinediones activate peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity, promoting adipogenesis in peripheral tissue, and reducing hepatic and skeletal muscle lipotoxicity[6][8]. The combination has no strong evidence in widespread use; each is used for their individual indications—spironolactone for hypertension, heart failure, and edema, and thiazolidinedione for Type 2 diabetes mellitus[2][6][3][8]. There are no branded pharmaceutical products or clinical studies identified combining these two agents as a single formulation.

Other names

spironolactone + thiazolidinedione